InvestSMART

Vitrafy Life Sciences Limited (ASX: VFY) - Announcements

- Current share price for VFY : $2.900

ASX company news and announcements for Vitrafy Life Sciences Limited (VFY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vitrafy Life Sciences Limited (VFY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vitrafy Life Sciences Limited (VFY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vitrafy Life Sciences Limited (VFY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$181 Application for quotation of securities - VFY 10 Jul 2026 9:05AM $3.010 $2.900 fallen by 3.65%
$181 Change of Director's Interest Notice - Correction 9 Jul 2026 9:31AM $2.960 $2.900 fallen by 2.03%
$181 Change of Director's Interest Notices 9 Jul 2026 8:53AM $2.960 $2.900 fallen by 2.03%
$181 Application for quotation of securities - VFY 9 Jul 2026 8:21AM $2.960 $2.900 fallen by 2.03%
$181 Expiry of Voluntary Escrow Restrictions 8 Jul 2026 10:19AM $2.950 $2.900 fallen by 1.69%
$181 Results of Oversubscribed Share Purchase Plan 8 Jul 2026 8:25AM $3.010 $2.900 fallen by 3.65%
$181 Vitrafy Share Purchase Plan Opens - SPP Offer Booklet 19 Jun 2026 8:20AM $2.760 $2.900 risen by 5.07%
$181 Cleansing Notice 18 Jun 2026 8:22AM $2.800 $2.900 risen by 3.57%
$181 Application for quotation of securities - VFY 18 Jun 2026 8:22AM $2.800 $2.900 risen by 3.57%
$181 Proposed issue of securities - VFY 12 Jun 2026 9:33AM $3.800 $2.900 fallen by 23.68%
$181 Vitrafy Equity Raising Presentation 12 Jun 2026 9:33AM $3.800 $2.900 fallen by 23.68%
$181 Vitrafy Placement Completion and SPP Announcement 12 Jun 2026 9:32AM $3.800 $2.900 fallen by 23.68%
$181 Trading Halt 10 Jun 2026 8:32AM $3.800 $2.900 fallen by 23.68%
$181 Vitrafy Investor Presentation 3 Jun 2026 8:20AM $2.790 $2.900 risen by 3.94%
$181 Vitrafy enters a partnership with Vitalant Innovation Center 2 Jun 2026 10:08AM $2.660 $2.900 risen by 9.02%
$181 Phase 2 USAISR Platelet Results Investor Briefing 22 May 2026 8:23AM $2.340 $2.900 risen by 23.93%
$181 Phase 2 USAISR Platelet Results Investor Presentation 22 May 2026 8:23AM $2.340 $2.900 risen by 23.93%
$181 Final US Army Phase 2 Platelet Results 22 May 2026 8:20AM $2.340 $2.900 risen by 23.93%
$181 Quarterly Investor Briefing Presentation 28 Apr 2026 8:22AM $1.990 $2.900 risen by 45.73%
$181 Q3 FY26 Quarterly Activities Report and Appendix 4C 28 Apr 2026 8:21AM $1.990 $2.900 risen by 45.73%
$181 Vitrafy Q3 FY26 Investor Briefing 23 Apr 2026 4:27PM $1.895 $2.900 risen by 53.03%
$181 USAISR Completes Phase 2 Platelet Study 8 Apr 2026 8:23AM $1.730 $2.900 risen by 67.63%
$181 NWR Virtual Healthcare Conference Presentation 26 Mar 2026 8:14AM $1.680 $2.900 risen by 72.62%
$181 Vitrafy to present at NWR Virtual Healthcare Conference 24 Mar 2026 5:40PM $1.650 $2.900 risen by 75.76%
$181 Change of Director's Interest Notice 19 Feb 2026 11:09AM $1.710 $2.900 risen by 69.59%

1 - 25 of 108 results

Page 1 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.